Cargando…

Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases

OBJECTIVE: To describe novel clinical features of GlyRα1-IgG–positive patients. METHODS: Patients with a positive serum GlyRα1-IgG were identified during a 2-year period from July 2016 to December 2018 at 2 academic centers and followed prospectively. All patients in this series were evaluated in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Piquet, Amanda L., Khan, Murtaza, Warner, Judith E.A., Wicklund, Matthew P., Bennett, Jeffrey L., Leehey, Maureen A., Seeberger, Lauren, Schreiner, Teri L., Paz Soldan, M. Mateo, Clardy, Stacey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624144/
https://www.ncbi.nlm.nih.gov/pubmed/31355325
http://dx.doi.org/10.1212/NXI.0000000000000592
Descripción
Sumario:OBJECTIVE: To describe novel clinical features of GlyRα1-IgG–positive patients. METHODS: Patients with a positive serum GlyRα1-IgG were identified during a 2-year period from July 2016 to December 2018 at 2 academic centers and followed prospectively. All patients in this series were evaluated in the Neuroimmunology and Autoimmune Neurology clinics at the University of Utah or the University of Colorado. RESULTS: Thirteen of 17 patients had phenotypes more typically associated with glutamic acid decarboxylase (GAD65) antibody syndromes, consisting of stiff-person syndrome (SPS) with parkinsonism or cerebellar signs. One patient with parkinsonism had a presentation similar to rapidly progressive multiple system atrophy with severe dysautonomia. Ten of 17 patients had various visual symptoms including visual snow, spider web–like images forming shapes and 3-dimensional images, palinopsia, photophobia, visual hallucinations, synesthesia, and intermittent diplopia. Three of 17 patients presented with primarily autoimmune epilepsy accompanied by psychiatric symptoms. CONCLUSIONS: Clinicians should consider testing for GlyR antibodies in GAD65 antibody–negative or low-positive GAD65 antibody patients with SPS-like presentations, especially in the setting of atypical features such as visual disturbances, parkinsonism, or epilepsy.